🚀 VC round data is live in beta, check it out!
Zura Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zura Bio and similar public comparables like Larimar Therapeutics, Fulcrum Therapeutics, Entrada Therapeutics, Knight Therapeutics and more.
Zura Bio Overview
About Zura Bio
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Founded
2022
HQ
Employees
30
Website
Sectors
Financials (LTM)
EV
$422M
Zura Bio Financials
Zura Bio reported last 12-month revenue of —.
In the same LTM period, Zura Bio generated — in gross profit and had net loss of ($93M).
Revenue (LTM)
Zura Bio P&L
In the most recent fiscal year, Zura Bio reported revenue of — and EBITDA of ($75M).
Zura Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($75M) | XXX | XXX | XXX |
| Net Profit | ($93M) | XXX | ($69M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zura Bio Stock Performance
Zura Bio has current market cap of $531M, and enterprise value of $422M.
Market Cap Evolution
Zura Bio's stock price is $5.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $422M | $531M | -1.8% | XXX | XXX | XXX | $-0.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZura Bio Valuation Multiples
Zura Bio trades at (5.6x) EV/EBITDA.
Zura Bio Financial Valuation Multiples
As of April 11, 2026, Zura Bio has market cap of $531M and EV of $422M.
Equity research analysts estimate Zura Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zura Bio has a P/E ratio of (5.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $531M | XXX | $531M | XXX | XXX | XXX |
| EV (current) | $422M | XXX | $422M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.6x) | XXX | XXX | XXX |
| EV/EBIT | (5.5x) | XXX | (5.6x) | XXX | XXX | XXX |
| P/E | (5.7x) | XXX | (7.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zura Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zura Bio Margins & Growth Rates
Zura Bio's revenue in the last fiscal year grew by —.
Zura Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.5M for the same period.
Zura Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zura Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Larimar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Entrada Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Knight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Opthea | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zura Bio M&A Activity
Zura Bio acquired XXX companies to date.
Last acquisition by Zura Bio was on XXXXXXXX, XXXXX. Zura Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zura Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZura Bio Investment Activity
Zura Bio invested in XXX companies to date.
Zura Bio made its latest investment on XXXXXXXX, XXXXX. Zura Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zura Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zura Bio
| When was Zura Bio founded? | Zura Bio was founded in 2022. |
| Where is Zura Bio headquartered? | Zura Bio is headquartered in United States. |
| How many employees does Zura Bio have? | As of today, Zura Bio has over 30 employees. |
| Who is the CEO of Zura Bio? | Zura Bio's CEO is Sandeep C. Kulkarni. |
| Is Zura Bio publicly listed? | Yes, Zura Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Zura Bio? | Zura Bio trades under ZURA ticker. |
| When did Zura Bio go public? | Zura Bio went public in 2023. |
| Who are competitors of Zura Bio? | Zura Bio main competitors are Larimar Therapeutics, Fulcrum Therapeutics, Entrada Therapeutics, Knight Therapeutics. |
| What is the current market cap of Zura Bio? | Zura Bio's current market cap is $531M. |
| Is Zura Bio profitable? | No, Zura Bio is not profitable. |
| What is the current net income of Zura Bio? | Zura Bio's last 12 months net income is ($93M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.